Market Summary
USD13.17+0.06
Market Closed0.46%
INVA Stock Price
INVA RSI Chart
INVA Valuation
INVA Price/Sales (Trailing)
INVA Profitability
INVA Fundamentals
INVA Revenue
INVA Earnings
Price Action
52 Week Range
10.6415.67
(Low)(High)
Last 7 days
0.2%
Last 30 days
14.2%
Last 90 days
19.8%
Trailing 12 Months
-13.2%
INVA Financial Health
INVA Investor Care
Peers (Alternatives to Innoviva)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
JNJ | 409.0B | 96.3B | -3.62% | -9.57% | 32.14 | 4.25 | 1.46% | -35.83% |
LLY | 398.5B | 27.7B | 2.58% | 47.15% | 70.08 | 14.39 | -5.56% | -7.22% |
MRK | 272.8B | 57.9B | -4.82% | 28.79% | 17.88 | 4.63 | 7.21% | -8.11% |
PFE | 230.9B | 93.0B | -0.23% | -25.99% | 7.36 | 2.3 | 0.56% | 16.36% |
BMY | 150.1B | 45.8B | -1.47% | -11.26% | 23.72 | 3.25 | -2.37% | 16.96% |
| MID-CAP | ||||||||
PRGO | 5.0B | 4.6B | -12.00% | -16.92% | -35.25 | 1.11 | 8.46% | -29.07% |
RETA | 3.5B | 1.5M | -8.84% | 225.36% | -11.32 | 1.6K | -86.94% | -16.59% |
| SMALL-CAP | ||||||||
SUPN | 1.8B | 668.5M | -9.91% | 19.28% | 34.95 | 2.72 | 11.17% | -29.04% |
TLRY | 1.6B | 596.3M | -7.75% | -62.41% | -0.89 | 2.66 | -3.41% | -3791.67% |
INVA | 866.9M | 271.5M | 14.22% | -13.24% | 3.94 | 3.19 | -31.50% | -40.28% |
CRON | 666.4M | 112.3M | -6.91% | -41.08% | -4.29 | 5.94 | 7.69% | 41.96% |
ACRS | 590.7M | 30.8M | -2.33% | -39.30% | -6.14 | 19.16 | 378.90% | -19.01% |
OCUL | 536.4M | 51.7M | 11.79% | 117.61% | -6.04 | 10.38 | 4.69% | -299.77% |
CGC | 401.1M | 478.9M | -31.81% | -82.48% | -0.13 | 0.84 | -31.50% | -634.70% |
ENDP | 94.1M | 2.2B | -43.99% | -88.43% | -0.03 | 0.04 | -25.47% | -292.77% |
Financials for Innoviva
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Revenue | -4.8% | 272 | 285 | 373 | 404 | 396 |
| Operating Expenses | -144.6% | -59.81 | 134 | 113 | - | - |
| S&GA Expenses | 20.8% | 77.00 | 64.00 | 49.00 | 24.00 | 17.00 |
| R&D Expenses | 16.3% | 48.00 | 41.00 | 31.00 | 20.00 | 6.00 |
| EBITDA | -27.7% | 319 | 441 | 275 | 392 | - |
| EBITDA Margin | -5.4% | 1.12* | 1.18* | 0.68* | 0.99* | - |
| Earnings Before Taxes | -1.2% | 283 | 287 | 408 | 245 | 361 |
| EBT Margin | -8.0% | 1.01* | 1.09* | 0.61* | 0.91* | - |
| Interest Expenses | 9.0% | 17.00 | 16.00 | 17.00 | 16.00 | 17.00 |
| Net Income | -34.1% | 220 | 334 | 208 | 297 | - |
| Net Income Margin | -13.8% | 0.77* | 0.90* | 0.51* | 0.75* | - |
| Free Cahsflow | -30.7% | 202 | 291 | 372 | 378 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Assets | -8.3% | 1,130 | 1,231 | 1,328 | 1,138 | 1,107 |
| Current Assets | -33.2% | 296 | 444 | 455 | 400 | 318 |
| Cash Equivalents | -50.5% | 144 | 291 | 301 | 284 | 217 |
| Inventory | -11.2% | 50.00 | 56.00 | 71.00 | - | - |
| Net PPE | 5.9% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Goodwill | 4.6% | 28.00 | 27.00 | 16.00 | 6.00 | 6.00 |
| Current Liabilities | -71.7% | 38.00 | 135 | 164 | 126 | 109 |
| LT Debt, Non Current | 0.1% | 445 | 444 | 444 | 443 | 443 |
| Shareholder's Equity | -0.8% | 561 | 566 | 641 | 565 | 552 |
| Retained Earnings | 17.0% | -170 | -204 | -136 | -402 | -403 |
| Additional Paid-In Capital | -3.4% | 1,125 | 1,164 | 1,171 | 1,184 | 1,183 |
| Shares Outstanding | -4.9% | 66.00 | 69.00 | 70.00 | 70.00 | 70.00 |
| Minority Interest | NaN% | - | - | 177 | 166 | - |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Cashflow From Operations | -35.9% | 129 | 202 | 291 | 372 | 378 |
| Share Based Compensation | 8.8% | 8.00 | 7.00 | 7.00 | 3.00 | 3.00 |
| Cashflow From Investing | 189.7% | 51.00 | -56.63 | -67.86 | -165 | -73.04 |
| Cashflow From Financing | -355.0% | -252 | -55.57 | -57.63 | 34.00 | -370 |
| Buy Backs | 479.1% | 49.00 | 9.00 | 0.00 | 0.00 | 0.00 |
Risks for INVA
What is the probability of a big loss on INVA?
73.1%
Probability that Innoviva stock will be more than 20% underwater in next one year
61.9%
Probability that Innoviva stock will be more than 30% underwater in next one year.
39.6%
Probability that Innoviva stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does INVA drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Innoviva was unfortunately bought at previous high price.
Drawdowns
Returns for INVA
Cumulative Returns on INVA
2.3%
7-Year Cumulative Returns
-2.5%
5-Year Cumulative Returns
-1.7%
3-Year Cumulative Returns
What are the long-term rolling returns for INVA?
FIve years rolling returns for Innoviva.
Annualized Returns
Which funds bought or sold INVA recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-06-01 | MACQUARIE GROUP LTD | reduced | -90.89 | -765,000 | 64,000 | -% |
2023-05-26 | ProShare Advisors LLC | reduced | -11.81 | -52,413 | 156,195 | -% |
2023-05-25 | Brandywine Global Investment Management, LLC | sold off | -100 | -2,423,460 | - | -% |
2023-05-23 | ROYCE & ASSOCIATES LP | added | 18.17 | 4,375 | 1,320,980 | 0.01% |
2023-05-22 | EMC Capital Management | unchanged | - | -57,000 | 322,000 | 0.27% |
2023-05-22 | PUTNAM INVESTMENTS LLC | unchanged | - | -376,856 | 5,394,980 | 0.01% |
2023-05-22 | AMERIPRISE FINANCIAL INC | reduced | -0.12 | -501,375 | 2,795,620 | -% |
2023-05-22 | PUTNAM INVESTMENTS LLC | added | 20.14 | 1,330,760 | 67,592,000 | 0.11% |
2023-05-18 | JPMORGAN CHASE & CO | reduced | -10.62 | -1,073,000 | 3,374,000 | -% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | reduced | -6.73 | -602,000 | 2,289,000 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Innoviva News
Schedule 13G FIlings of Innoviva
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| May 15, 2023 | sarissa capital management lp | 10.54% | 6,904,000 | SC 13D/A | |
| Feb 14, 2023 | putnam investments llc | 7.6% | 5,329,107 | SC 13G | |
| Feb 13, 2023 | renaissance technologies llc | 6.06% | 4,229,607 | SC 13G/A | |
| Feb 10, 2023 | blackrock inc. | 15.2% | 10,611,839 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 10.13% | 7,072,212 | SC 13G/A | |
| Feb 02, 2023 | westfield capital management co lp | 5.88% | 4,106,136 | SC 13G/A | |
| Jan 26, 2023 | blackrock inc. | 10.6% | 5,671,100 | SC 13G/A | |
| Jan 20, 2023 | blackrock inc. | 10.6% | 5,671,100 | SC 13G | |
| Jul 11, 2022 | vanguard group inc | 10.00% | 6,970,950 | SC 13G/A | |
| Feb 11, 2022 | renaissance technologies llc | 7.62% | 5,295,133 | SC 13G/A |
INVA Fair Value
Recent SEC filings of Innoviva
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| May 30, 2023 | 4 | Insider Trading | |
| May 24, 2023 | 4 | Insider Trading | |
| May 24, 2023 | 4 | Insider Trading | |
| May 24, 2023 | 4 | Insider Trading | |
| May 24, 2023 | 4 | Insider Trading | |
| May 24, 2023 | 4 | Insider Trading | |
| May 24, 2023 | 4 | Insider Trading | |
| May 24, 2023 | 8-K | Current Report | |
| May 24, 2023 | 8-K | Current Report | |
| May 23, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for INVA
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-05-30 | DENNER ALEXANDER J | bought | 1,560,650 | 13.0054 | 120,000 | - |
2023-05-26 | DENNER ALEXANDER J | bought | 393,729 | 13.1243 | 30,000 | - |
2023-05-25 | DENNER ALEXANDER J | bought | 654,330 | 13.0866 | 50,000 | - |
2023-05-22 | Srivastava Sapna | acquired | - | - | 16,495 | - |
2023-05-22 | DiPaolo Mark | acquired | - | - | 16,495 | - |
2023-05-22 | Schlesinger Sarah J. | acquired | - | - | 16,495 | - |
2023-05-22 | Birx Deborah | acquired | - | - | 16,495 | - |
2023-05-22 | Odysseas Kostas D | acquired | - | - | 16,495 | - |
2023-05-22 | Haimovitz Jules | acquired | - | - | 16,495 | - |
2023-05-19 | Zhen Marianne | sold (taxes) | -10,560 | 13.47 | -784 | chief accounting officer |
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
INVA Income Statement
2023-03-31CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
|---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
| Revenue: | ||
| Total revenue | $ 76,372 | $ 90,059 |
| Expenses: | ||
| Selling, general and administrative | 19,735 | 6,492 |
| Research and development | 12,588 | 5,838 |
| Amortization of acquired intangible assets | 3,805 | 0 |
| Loss on extinguishment of debt | 0 | 20,662 |
| Changes in fair values of equity method investments, net | (15,817) | 11,950 |
| Changes in fair values of other equity and long-term investments, net | 2,164 | (2,539) |
| Interest and dividend income | (3,365) | (322) |
| Interest expense | 4,427 | 3,010 |
| Other expense, net | 1,346 | 250 |
| Total expenses | 35,232 | 45,341 |
| Income before income taxes | 41,140 | 44,718 |
| Income tax expense, net | 6,275 | 6,860 |
| Net income | 34,865 | 37,858 |
| Net income attributable to noncontrolling interests | 0 | 22,085 |
| Net income attributable to Innoviva stockholders | $ 34,865 | $ 15,773 |
| Basic net income per share attributable to Innoviva stockholders | $ 0.51 | $ 0.23 |
| Diluted net income per share attributable to Innoviva stockholders | $ 0.42 | $ 0.20 |
| Shares used to compute Innoviva basic and diluted net income per share: | ||
| Shares used to compute basic net income per share | 67,786 | 69,544 |
| Shares used to compute diluted net income per share | 89,788 | 93,730 |
| Royalty revenue | ||
| Revenue: | ||
| Total revenue | $ 56,858 | $ 90,059 |
| Net product sales | ||
| Revenue: | ||
| Total revenue | 11,514 | 0 |
| Expenses: | ||
| Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding depreciation and amortization of intangible assets) | 8,749 | 0 |
| License revenue | ||
| Revenue: | ||
| Total revenue | 8,000 | 0 |
| License | ||
| Expenses: | ||
| Cost of license revenue | $ 1,600 | $ 0 |
INVA Balance Sheet
2023-03-31CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 144,049 | $ 291,049 |
| Accounts receivable , net | 15,490 | 9,401 |
| Receivables from collaboration arrangement | 60,314 | 54,672 |
| Inventory | 49,653 | 55,897 |
| Prepaid expenses | 24,119 | 29,559 |
| Other current assets | 2,821 | 2,933 |
| Total current assets | 296,446 | 443,511 |
| Property and equipment, net | 180 | 170 |
| Equity Method Investment | 54,971 | 39,154 |
| Equity and long-term investments | 400,894 | 363,859 |
| Capitalized fees paid, net | 94,151 | 97,607 |
| Right-of-use assets | 2,973 | 3,265 |
| Goodwill | 27,946 | 26,713 |
| Intangible assets | 248,314 | 252,919 |
| Other assets | 3,893 | 4,299 |
| Total assets | 1,129,768 | 1,231,497 |
| Current liabilities: | ||
| Accounts payable | 5,933 | 2,939 |
| Accrued personnel-related expenses | 4,223 | 8,022 |
| Accrued interest payable | 833 | 4,359 |
| Deferred revenue | 2,094 | 2,094 |
| Convertible subordinated notes due 2023, net of issuance costs | 0 | 96,193 |
| Income tax payable | 154 | 154 |
| Other accrued liabilities | 24,900 | 21,207 |
| Total current liabilities | 38,137 | 134,968 |
| Long-term debt, net of discount and issuance costs | 444,692 | 444,180 |
| Other long-term liabilities | 70,133 | 70,918 |
| Deferred tax liabilities, net | 5,392 | 5,771 |
| Income tax payable, long-term | 9,921 | 9,872 |
| Commitments and contingencies (Note 12) | ||
| Stockholders' equity: | ||
| Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding | 0 | 0 |
| Common stock: $0.01 par value, 200,000 shares authorized, 65,824 and 69,188 issued and outstanding as of March 31, 2023 and December 31, 2022, respectively | 659 | 692 |
| Treasury stock: at cost, 32,005 shares as of March 31, 2023 and December 31, 2022, respectively | (393,829) | (393,829) |
| Additional paid-in capital | 1,124,709 | 1,163,836 |
| Accumulated deficit | (170,046) | (204,911) |
| Total stockholders' equity | 561,493 | 565,788 |
| Total liabilities and stockholders' equity | $ 1,129,768 | $ 1,231,497 |